Envoy Medical Inc (COCH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$7.10-0.28%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · COCH
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“We submitted the first of four modules of our modular PMA application and our pivotal clinical trial continued to advance.
Stated in 1 of 1 supplied quarters. Management reported: “The Company submitted the first module of its Modular Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for its Breakthrough Device-designated investigational Acclaim® cochlear implant.” “These participants achieved a mean Consonant-Nucleus-Consonant (“CNC”) word recognition score of 53.2% at their 12-month visits, compared to a pre-implantation baseline of 15.2%, a 38.0 percentage point improvement and continued gains from the 24.0 percentage point improvement reported at six months.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We continue to be encouraged by the trial’s progress and remain focused on advancing toward PMA submission and, ultimately, commercialization.”
As of June 30, 2026, cash was approximately $19,679.
Stated in 1 of 1 supplied quarters. Management reported: “As of June 30, 2026, cash was approximately $19,679.” “2 As of March 31, 2026, cash was approximately $25,251.”
“2 As of March 31, 2026, cash was approximately $25,251.”
The Australian and European patent offices granted the Company four patents relating to important innovations in implantable system design, signal analysis, and battery recharge safety, further stren…
Stated in 1 of 1 supplied quarters. Management reported: “The Australian and European patent offices granted the Company four patents relating to important innovations in implantable system design, signal analysis, and battery recharge safety, further strengthening the Company’s intellectual property position in the implantable medical device and cochlear implant industries.” “● Expanded Intellectual Property Portfolio As of February 20, 2026, Envoy Medical has expanded its global IP portfolio to 47 patents across North America, Europe, Asia, and Australia.”
“● Expanded Intellectual Property Portfolio As of February 20, 2026, Envoy Medical has expanded its global IP portfolio to 47 patents across North America, Europe, Asia, and Australia.”
The Reverse Split is intended to maintain compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s Common Stock on Nasdaq and may improve trading liquidity by in…
Stated in a supplied disclosure. Management reported: “The Reverse Split is intended to maintain compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s Common Stock on Nasdaq and may improve trading liquidity by increasing the price per share of our Class A common stock, which could enable a broader range of institutions to invest.”
Complete pivotal-trial follow-up and submit the remaining modules of the Acclaim cochlear implant's modular PMA application to the FDA.
Over the trailing year it converted 1.31x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
38 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.